Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 16/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 16/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 16/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10875780 | 0.95 | ADRB2 (0.50) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| SCHEMBL19316653 | 0.94 | MAPT (0.50) | ADRB2ADRB1ADRB3TSHRSLC1A5 | |
| SCHEMBL13002778 | 0.90 | ADRB2 (0.59) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| SCHEMBL10706533 | 0.90 | MAPT (0.54) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| SCHEMBL9792359 | 0.90 | ADRB2 (0.59) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| SCHEMBL19316643 | 0.89 | PTPN1 (0.42) | ADRB2ADRB1ADRB3TSHRSLC1A5 | |
| SCHEMBL23601564 | 0.88 | ADRB2 (0.45) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| SCHEMBL21422410 | 0.88 | ADRB2 (0.49) | ADRB2ADRB1ADRB3TSHR | |
| SCHEMBL24845121 | 0.88 | ADRB2 (0.49) | ADRB2ADRB1ADRB3TSHRALDH1A1 | |
| SCHEMBL12126370 | 0.88 | ADRB2 (0.58) | ADRB2ADRB1ADRB3TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | TOKUYAMA DENTAL CORPORATION (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | TOKUYAMA DENTAL CORPORATION (JP) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | H1-0, VMP1, CHRM1 | ADRB2 735/4885ADRB1 850/4885ADRB3 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.